Metabolism of bile salts in mice influences spore germination in clostridium difficile

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Giel, Jennifer L ^a,c   Sorg, Joseph A ^b   Sonenshein, Abraham L ^b   Zhu, Jun ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UBC Envision Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BILE SALT; COLESTYRAMINE; BILE ACID; PRIMER DNA;

ARTICLE; CLOSTRIDIUM DIFFICILE; COLONY FORMATION; COMMENSAL; CONTROLLED STUDY; INTESTINE FLORA; METABOLISM; MOUSE; NONHUMAN; SPORE GERMINATION; ANIMAL; BACTERIAL SPORE; GROWTH, DEVELOPMENT AND AGING; INTESTINE; MICROBIOLOGY; NUCLEOTIDE SEQUENCE;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; MUS;

ANIMALS; BASE SEQUENCE; BILE ACIDS AND SALTS; CLOSTRIDIUM DIFFICILE; DNA PRIMERS; INTESTINES; MICE; SPORES, BACTERIAL;

EID: 77649282955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008740     Document Type: Article

References (44)

1. Blossom DB, McDonald LC (2007) The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 45: 222-227.
2. Hurley BW, Nguyen CC (2002) The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 162: 2177-2184.
3. Kramer A, Schwebke I, Kampf G (2006) How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 6: 130.
4. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM (2007) The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28: 1219-1227.
5. O'Connor JR, Johnson S, Gerding DN (2009) Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924.
6. Razavi B, Apisarnthanarak A, Mundy LM (2007) Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 35: 300-307.
7. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY (2009) National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 37: 263-270.
8. Vollaard EJ, Clasener HA (1994) Colonization resistance. Antimicrob Agents Chemother 38: 409-414.
9. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, et al. (2006) The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38: 779-786.
10. Bartlett JG (2008) Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 46 Suppl 1: S4-11.
11. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, et al. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40: 1586-1590.
12. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, et al. (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40: 1591-1597.
13. Setlow P (2003) Spore germination. Curr Opin Microbiol 6: 550-556.
14. Sorg JA, Sonenshein AL (2008) Bile salts and glycine as co-germinants for Clostridium difficile spores. J Bacteriol 190: 2505-2512.
15. Wilson KH (1983) Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18: 1017-1019.
16. Wilson KH, Kennedy MJ, Fekety FR (1982) Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol 15: 443-446.
17. Corthier G, Dubos F, Raibaud P (1985) Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol 49: 250-252.
18. Keel MK, Songer JG (2006) The comparative pathology of Clostridium difficile-associated disease. Vet Pathol 43: 225-240.
19. Pultz NJ, Donskey CJ (2005) Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 49: 3529-3532.
20. Popoff MR, Rubin EJ, Gill DM, Boquet P (1988) Actin-specific ADPribosyltransferase produced by a Clostridium difficile strain. Infect Immun 56: 2299-2306.
21. 2-regulated genes in Escherichia coli. Mol Microbiol 60: 1058-1075.
22. Wadolkowski EA, Laux DC, Cohen PS (1988) Colonization of the streptomycin-treated mouse large intestine by a human fecal Escherichia coli strain: role of growth in mucus. Infect Immun 56: 1030-1035.
23. Macdonald IA, Williams CN, Musial BC (1980) 3α-, 7α-, and 12α-OH group specific enzymic analysis of biliary bile acids: comparison with gas-liquid chromatograpy. J Lipid Res 21: 381-385.
24. Monaghan T, Boswell T, Mahida YR (2009) Recent advances in Clostridium difficile-associated disease. Postgrad Med J 85: 152-162.
25. Fekety R, Silva J, Browne RA, Rifkin GD, Ebright JR (1979) Clindamycin-induced colitis. Am J Clin Nutr 32: 244-250.
26. Merrigan M, Sambol S, Johnson S, Gerding DN (2003) Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe 9: 91-95.
27. Sorg JA, Sonenshein AL (2009) Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 191: 1115-1117.
28. Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47: 241-259.
29. Nerandzic MM, Pultz MJ, Donskey CJ (2009) Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother 53: 4133-4137.
30. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, et al. (2009) Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77: 3661-3669.
31. Onderdonk AB, Cisneros RL, Bartlett JG (1980) Clostridium difficile in gnotobiotic mice. Infect Immun 28: 277-282.
32. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, et al. (2008) A mouse model of Clostridium difficile-associated disease. Gastroenterology 135: 1984-1992.
33. Eyssen HJ, Parmentier GG, Mertens JA (1976) Sulfate bile acids in germ-free and conventional mice. Eur J Biochem 66: 507-514.
34. Ariano RE, Zhanel GG, Harding GK (1990) The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. CMAJ 142: 1049-1051.
35. Liacouras CA, Piccoli DA (1996) Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol 22: 186-189.
36. Murphy C, Vernon M, Cullen M (2006) Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 35: 85-86.
37. Taylor NS, Bartlett JG (1980) Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141: 92-97.
38. Hofmann AF, Hagey LR (2008) Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65: 2461-2483.
39. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, et al. (2009) Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 77: 2367-2375.
40. Edenharder R (1984) Dehydroxylation of cholic acid at C12 and epimerization at C5 and C7 by Bacteroides species. J Steroid Biochem 21: 413-420.
41. Hashimoto S, Igimi H, Uchida K, Satoh T, Benno Y, et al. (1996) Effects of beta-lactam antibiotics on intestinal microflora and bile acid metabolism in rats. Lipids 31: 601-609.
42. Powell RC, Nunes WT, Harding RS, Vacca JB (1962) The influence of nonabsorbable antibiotics on serum lipids and the excretion of neutral sterols and bile acids. Am J Clin Nutr 11: 156-168.
43. Samuel P, Holtzman CM, Meilman E, Sekowski I (1973) Effect of neomycin and other antibiotics on serum cholesterol levels and on 7alpha-dehydroxylation of bile acids by the fecal bacterial flora in man. Circ Res 33: 393-402.
44. Stiefel U, Nerandzic MM, Koski P, Donskey CJ (2008) Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J Antimicrob Chemother 62: 1105-1108.